Evidence map›Paper›PMID 42623114›Full record

ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Innovations in Aptamer Technology: SELEX To Intelligent Molecular Engineering and Clinical Translation.

Arshad Mehmood, Miraj Ud Din, Sunil Kumar Shah, Muhammad Faizan Munawer, Munazzah Marryum, Hui Jiang, Xiaohui Liu, Xuemei Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arshad MehmoodState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.ORCID https://orcid.org/0000-0002-7547-4767
Miraj Ud DinState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Sunil Kumar ShahState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Muhammad Faizan MunawerState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Munazzah MarryumState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Hui JiangState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Xiaohui LiuState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Xuemei WangState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.

Funding

MOST | National Natural Science Foundation of China (NSFC) 82027806MOST | National Natural Science Foundation of China (NSFC) 92461308MOST | National Natural Science Foundation of China (NSFC) U25A20566
6 · The paper itself

Abstract

Aptamers-short, single-stranded nucleic acids capable of folding into complex three-dimensional structures-have evolved from biochemical curiosities into programmable molecular interfaces with expanding diagnostic and therapeutic relevance. Through systematic evolution of ligands by exponential enrichment (SELEX), aptamers exploit the structural plasticity of nucleic acids to achieve high-affinity and high-specificity target recognition. Innovations in chemical modification, high-throughput sequencing, microfluidics, nanotechnology, and artificial intelligence (AI) have redefined aptamer discovery and translational potential. Aptamers transition from antibody alternatives to programmable molecular systems capable of sensing, computation, and controlled actuation in biological environments.

Indexed as

Aptamers, NucleotideArtificial IntelligenceSELEX Aptamer TechniqueTranslational Research, BiomedicalAnimalsHumansNanotechnologyAptamers, Nucleotideaptamer‐based diagnosticsaptamersartificial intelligence‐guided molecular designnucleic acid therapeuticsprogrammable molecular interfacesSELEX

Identifiers

PMID42623114
PMCPMC13492503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.